Try Alerts Free   |   Login
Health Care › Surgical And Medical Instruments And Apparatus

TNDM Price Correlated With Financials For Tandem Diabetes Care

Free historical financial statements for Tandem Diabetes Care Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 33 quarters since 2014. Compare with TNDM stock chart to see long term trends.

TNDM Stock Compared to Quarterly

TNDM Income Statement

Revenue, Net:175907000
Revenue Per Share:2.7501
Cost of Goods & Services Sold:84814000
Gross Profit:91093000
Selling, General & Admin Expense:73271000
Research & Development Expense:33160000
Total Operating Expenses:106431000
Operating Income:-16439000
Income Taxes:-1724000
Net Income:-14715000
Earnings Per Share, Basic:-0.23
Shares Outstanding, Basic Avg:63962732

TNDM Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:3628000
Change in Accounts Receiveable:-15729000
Net Cash from Operations:13800000
Net Cash from Operations Per Share:0.2158
Net Cash from Financing Activities:3500000
Property, Plant & Equipment Purchases:2643000
Net Cash from Investing Activities:5197000
Net Change in Cash & Equivalents:22500000

TNDM Balance Sheet

Cash and Cash Equivalents:93681000
Short-Term Investments:541710000
Accounts Receivable, Net:94133000
Inventories:79987000
Total Current Assets:818464000
Property, Plant & Equipment, Net:49987000
Total Assets:1015277000
Accounts Payable:45341000
Total Short-Term Liabilities:131815000
Total Liabilities:577895000

Insider Trading

 
Change
Value
Transaction
SEC Form 4
Vosseller Leigh   EVP & CHIEF FINANCIAL OFFICER
2,500 sh at $75
$186,528
Buy
Sheridan John F   PRESIDENT & CEO
2,500 sh at $70
$174,750
Buy
Howell Peyton R   Director
2,000 sh at $75
$149,695
Buy
COMPANY PROFILE
Organization and Basis of Presentation The Company

Tandem Diabetes Care, Inc. is a medical device company focused on the design, development and commercialization of technology solutions for people living with diabetes. Tandem Diabetes Care, Inc. is incorporated in the state of Delaware. Unless the context requires otherwise, the terms the “Company” or “Tandem” refer to Tandem Diabetes Care, Inc., together with its wholly-owned subsidiaries in the U.S. and Canada.

The Company manufactures, sells and supports insulin pump products that are designed to address the evolving needs and preferences of differentiated segments of the insulin-dependent diabetes market. The Company’s manufacturing, sales and support activities principally focus on the t:slim X2 Insulin Delivery System (t:slim X2), the Company’s flagship pump platform which is capable of remote software updates and is designed to display continuous glucose monitoring (CGM) sensor information directly on the pump home screen. The Company’s insulin pump products are compatible with other complementary digital health offerings, such as the t:connect cloud-based diabetes management application (t:connect) and the Tandem Device Updater, a Mac and PC-compatible tool which offers and supports updates of the Company’s insulin pump software from a personal computer. The Company’s insulin pump products are generally considered durable medical equipment and have an expected lifespan of at least four years. In addition to insulin pumps, the Company sells disposable products that are used together with the pumps and are replaced every few days, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to a user’s body, as well as other accessories for enhanced usability.

Basis of Presentation and Principles of Consolidation

The Company has prepared the accompanying consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. The statements include the accounts of Tandem Diabetes Care, Inc. and its wholly-owned subsidiaries in the U.S. and Canada. All significant intercompany balances and transactions have been eliminated in consolidation.

The functional currency of the Company’s foreign subsidiary is the local currency. The Company translates the financial statements of its foreign subsidiary into U.S. dollars using period-end exchange rates for assets and liabilities and average exchange rates for each period for revenue, costs and expenses. Translation related adjustments are included in other comprehensive income (loss), and in accumulated other comprehensive income (loss) in the stockholders’ equity section of the Company’s consolidated balance sheets. Foreign exchange gains or losses resulting from balances denominated in a currency other than the functional currency are recognized in interest income and other, net in the Company’s consolidated statements of operations.

Data imported from Tandem Diabetes Care Inc SEC filings. Check original filings before making any investment decision.